Search for: "United States v. General Research Laboratories"
Results 241 - 260
of 333
Sorted by Relevance
|
Sort by Date
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey… [read post]
15 Aug 2022, 2:35 pm
An AMT liability generally arises where the tentative minimum tax exceeds the sum of the corporation’s regular tax liability plus the corporation’s base erosion and anti-abuse tax (“BEAT”) imposed under Section 59A. [read post]
29 Apr 2011, 1:03 pm
Although he did not refer to Ti818 by name, he testified that as of the filing date of the '317 patent, the best way of making PET in the research laboratory to achieve the claimed TCH, absorbance, and luminosity values used a combination of titanium catalysts, cobalt, and carbon black as the HUR additive. [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade… [read post]
30 May 2008, 9:09 am
: (Spicy IP), India: DCGI preparing document to implement patent-registration linkage: (Spicy IP), New Zealand: Generic pharmaceutical companies taking advantage of NZ IP laws and medicines regulations: (International Law Office), Uganda: Cipla licenses ARV technology into Uganda: (Afro-IP), US: Money saved through generic prescriptions: (GenericsWeb), US: Government plans to keep close tab on drug patent settlements: (GenericsWeb), US: FTC reports 14 deals to delay… [read post]
6 Jun 2008, 6:49 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: YouTube – Prince demands removal of song from YouTube, Radiohead demand it is put back online: (Techdirt), (Electronic Frontier Foundation), (The Trademark Blog), Japan planning fair use provision: (Michael Geist), (Techdirt), (IP Justice), (Patry Copyright Blog), Judge rejects Yoko Ono’s request for preliminary injunction… [read post]
27 Dec 2021, 10:05 pm
We write to supplement the November 12, 2021, letter with new research. [read post]
28 Mar 2008, 6:00 am
- Anonymity of policy research group quoted on pharma patenting policy and stats: (Spicy IP),Thailand: More news/reactions on compulsory licenses: (Generic Pharmaceuticals & IP),US: Follow-on biologic drugs and patent law: A potential disconnect? [read post]
21 Oct 2011, 1:31 pm
The changes further made the novelty defeating acts available wherever they occur in the world, thereby removing requirements related to occurrences in the United States. [read post]
25 Apr 2015, 11:03 am
Third, the Manual authors state that the doubling argument assumes the “[n]onacceleration of disease. [read post]
22 Jul 2015, 2:18 pm
Ambiguity between how much of the discourse in A2K is targeted at patent v. copyright. [read post]
20 Jun 2008, 8:07 am
– Marks & Clerk Biotechnology Report 2008: (IP finance), Pfizer and Daiichi-Sankyo’s bidding for Ranbaxy: (IP ThinkTank), (IAM), (Managing Intellectual Property), (GenericsWeb), Cutting Edge Information study reveals 53% of pharma patents approach expiration before litigation strategies are implemented: (Peter Zura's 271 Patent Blog), Quanta and agricultural biotechnology: (Holman’s Biotech IP Blog), Breakthough by WHO will give poor countries better access… [read post]
29 Dec 2019, 9:05 pm
FTC v. [read post]
28 Feb 2021, 12:47 pm
Tatel, United States Court of Appeals for the District of Columbia Circuit; and Steven R. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
30 Jul 2018, 9:30 pm
For example, in United States v. [read post]
8 May 2007, 5:27 am
Admissible or Admissibility: Any testimony, docu Âment or demonstrative material that is officially con Âsidered by the court by allowing it into evidence generally in compliance with the rules of evidence. [read post]
4 Sep 2012, 7:09 am
The judgment is an important one, not only because it found that isolated DNA did not fall under the laws of nature exception, despite the United States Supreme Court's remand that the case be reconsidered in light of the enlarged scope of the exception in Mayo Collaborative Services v Prometheus Laboratories (see the IPKat here and here), but also due to its discussion of the incentives behind innovation and the reasons given for its strict adherence to the… [read post]
30 Dec 2018, 3:03 am
In March, new research showed that music and football right holders had brought the most cases to London's High Court in the preceding year. [read post]
16 Oct 2009, 3:18 pm
The Commission on Dietary Supplement Labels (the Commission), a seven-member body that was established under DSHEA to "provide recommendations for...the regulation of label claims and statements for dietary supplements, including the use of literature in connection with the sale of dietary supplements and procedures for the evaluation of such claims," held public meetings around the United States from 1996 through 1997. [read post]
